[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liver-transplant-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liver-transplant-disorder":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,44,75,104,137,164,190,217],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100617175","viability-assessment-using-fmn-measured-in-perfusate-and-bile-during-normothermic-machine-perfusion-100617175",false,"NCT07315204","Viability Assessment Using FMN Measured in Perfusate and Bile During Normothermic Machine Perfusion","Viability Assessment Using Flavin Mononucleotide (FMN) Measured in Perfusate and Bile During Normothermic Machine Perfusion: an International, Multi-center Validation Study","Inclusion Criteria:\n\n* Age \\>18 years\n* Any graft type (DBD or DCD)\n* Any underlying recipient disease (i.e., end stage, liver tumour)\n* Any other donor risk factors and static cold storage time prior to NMP accepted by the participating center for transplantation in context of OrganOx metra use\n* Patients undergoing primary deceased donor liver transplantation where back-to-base NMP is used (OrganOx metra) from July 15, 2025 to December 31, 2027. (CCF only)\n* Patients who have undergone deceased donor liver transplantation where back-to-base NMP was used (OrganOx metra) from October 22, 2022 to July 14, 2025. (CCF only)\n\nExclusion Criteria:\n\n* Patients receiving a liver graft that is not perfused with OrganOx metra\n* Pediatric recipients (\\\u003C18years)\n* Patients listed for super urgent liver transplantation due to acute liver failure\n* Patients receiving combined organ transplant (heart+liver, lung+liver, liver+kidney, liver+intestine)\n* Patients receiving living donor liver transplant or a split (or reduced) liver transplantation or a domino graft.\n* Re-transplantations","ALL","18 Years",{"count":19,"type":20},850,"ESTIMATED","OBSERVATIONAL","Discarded perfusate samples will be collected from donors after circulatory death (DCD) or donors after brain death (DBD) organs during the machine perfusion period prior to transplantation by the study team. FMN will be measured as is standard of care for all machine perfusion liver transplant cases at Cleveland Clinic.\n\nParticipating centers will be provided with sample collection and shipping instructions to ensure sample preservation in accordance with IATA guidelines. Samples from outside sites will not be stored for future research and will be discarded once analysis is completed.\n\nAfter the collection of the samples from machine perfusion, the transplant procedure will continue according to standard process.",[24],"Liver Transplant Disorder",[26,27,28,29,30],"normothermic machine perfusion","flavin mononucleotide","graft viability","liver transplant","OrganOx metra","RECRUITING","2026-06-02",{"date":34,"type":35},"2026-06-04","ACTUAL",{"date":37,"type":35},"2026-03-13",{"date":39,"type":20},"2028-12-31",{"name":41,"class":42},"The Cleveland Clinic","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":54,"studyType":21,"phases":4,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":43},"100497764","endoscopic-management-of-non-anastomotic-biliary-strictures-following-liver-transplantation-100497764","NCT05761483","Endoscopic Management of Non-anastomotic Biliary Strictures Following Liver Transplantation.","Endoscopic Management of Non-anastomotic Biliary Strictures Following Liver Transplantation. Registry of the Italian Society of Digestive Endoscopy.","STEBINANSIED","Inclusion Criteria:\n\n* Age \\> 18\n* Non anastomotic biliary strictures diagnosed by direct cholangiogram (T-tube) or MRCP\n* Stricture involving the hepatic hilum until secondary branches\n* Increase of liver function tests\n* Signature of the informed consent\n\nExclusion Criteria:\n\n* Previopus endoscopic or percutaneous treatments\n* Patient candidate to metal stents placement\n* Previous surgery resulting in altered anatomy",{"count":53,"type":20},40,"2 Years","The study will evaluate the results of endoscopic treatment of NON-anastomotic biliary strictures following liver transplantation",[24,57,58,59,60],"Ischemic Cholangiopathy","Non-anastomotic Biliary Stricture","Biliary Stricture","Biliary Stents (Plastic)",[62,63,64,65],"ERCP","Biliary stents","Liver transplantation","Ischemic cholangiopathy","2026-01-27",{"date":68,"type":35},"2026-01-29",{"date":70,"type":35},"2020-03-12",{"date":72,"type":20},"2028-01-01",{"name":74,"class":42},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":94,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":43},"100551068","phase-1-a-study-of-siplizumab-in-aild-and-lt-patients-100551068","NCT06455280","A Study of SIPLIZUMAB in AILD and LT Patients","A 12-Month, Open-Label Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Siplizumab as Induction Therapy in Patients With Autoimmune Liver Diseases Undergoing Liver Transplantation (SET-SAIL)","SET-SAIL","Inclusion Criteria:\n\n1. Able to provide informed consent\n2. Age ≥ 18 years old\n3. Clinical diagnosis of AIH and\u002For PSC\n4. Listed for liver transplantation\n5. Epstein-Barr virus (EBV) seropositive within 12 months of screening\n\nExclusion Criteria:\n\n1. Presence or history of significant liver disease other than AIH or PSC, including viral hepatitis, alcohol-related liver disease and biopsy-proven non-alcoholic steatohepatitis\n2. Prior transplant\n3. Listed for multiorgan transplant\n4. Acute liver failure\n5. Known malignancy, including cholangiocarcinoma and hepatocellular carcinoma\n6. Other investigational products in the last 30 days or 5 half lives\n7. Pregnant\u002Flactating or unwilling to use contraception\n8. Leukopenia (WBC less than 2,000\u002Fmm3\n9. Absolute lymphocyte count \\\u003C 200\u002Fmm3\n10. Sero-positive for HIV-1\n11. Hepatitis C Virus (HCV) antibody or RNA positive (within 6 months of screening)\n12. HBsAg, hepatitis B virus (HBV) DNA or HBcAb positive (within 6 months of screening)\n13. Alcohol use exceeding 30g\u002Fday for men or 20g\u002Fday for women, and\u002For known phosphatidylethanol (PETH) level \\>80 in the 3 months prior to LT\n14. Untreated latent TB infection as detected by QuantiFERON Gold Plus Interferon Gamma Release Assay (IGRA) (or current standard interferon gamma release assay for TB)\n15. Receipt of any live-attenuated vaccine within 2 months of transplant.\n\nADDITIONAL exclusion criteria to be reviewed at the time of transplant\n\n1. Renal failure with dialysis or with estimated glomerular filtration rate (eGFR) \\\u003C 30 at the time of LT\n2. Model for end-stage liver disease (MELD)-Na score \\>30\n3. Donor features of Donation after Cardiac Death (DCD), HCV Ab or nucleic acid testing (NAT+), HBcAb or HBsAg+, or blood types A, B, and O incompatible organ",{"count":5,"type":20},"INTERVENTIONAL",[86],"PHASE1","There is a significant unmet need for safe and effective therapeutic approaches to prevent immune-mediated graft injury and its complications in liver transplant (LT) recipients with autoimmune liver disease (AILD) including autoimmune hepatitis and primary sclerosing cholangitis. Siplizumab is an anti-cluster of differentiation 2 (CD2) monoclonal antibody that has demonstrated a favorable safety profile of siplizumab in over 779 human subjects and has been shown to target memory T cells-a key driver in the immune processes surrounding rejection and autoimmunity post LT in AILD. The purpose of this pilot, open-label phase 1 study is to determine the safety of siplizumab for induction in patients with AILD undergoing LT.\n\nUp to eight (8) subjects will receive siplizumab 0.6 mg\u002Fkg\u002Fdose on the day of transplant (Day 0) and Day 4 post-transplant, for a total of two doses.\n\nAll subjects will be followed in the study for 12 months post-LT.",[89,24,90,91,92,93],"Autoimmune Liver Disease","Autoimmune Hepatitis","Primary Sclerosing Cholangitis","End Stage Liver DIsease","Cirrhosis, Liver",[89,24,90,91,92,93],"2025-11-19",{"date":97,"type":35},"2025-11-24",{"date":99,"type":35},"2024-09-11",{"date":101,"type":20},"2028-03-31",{"name":103,"class":42},"Elizabeth C. Verna",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":111,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":84,"phases":115,"briefSummary":117,"conditions":118,"keywords":122,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":4},"100603927","evaluation-of-liver-resection-using-harmonic-scalpel-versus-cavitron-ultrasonic-surgical-aspirator-cusa-100603927","NCT07142876","Evaluation Of Liver Resection Using Harmonic Scalpel Versus Cavitron Ultrasonic Surgical Aspirator (CUSA).","Evaluation Of Liver Resection Using Harmonic Scalpel Versus Cavitron Ultrasonic Surgical Aspirator (CUSA)","Inclusion Criteria:\n\n* patients needing liver resection in normal liver and cirrhotic liver child-pough A and early B\n* Age \\> 6 and \\\u003C 70 years old\n* One or two small (5 cm or less) hepatic lesions confined to the liver with no extra hepatic involvement\n* Patients with -ve markers for viral hepatitis\n\nExclusion Criteria:\n\n* patients with age \\\u003C 6 or \\> 70 years old\n* liver cirrhosis Child-pough C\n* liver cell failure\n* very large lesions including most of the liver tissue\n* hepatic lesions with vascular invasion\n* evidence of metastasis in cases with HCC\n* patients with +ve markers for viral hepatitis","6 Years","70 Years",{"count":114,"type":20},50,[116],"NA","Evaluation Of Liver Resection Using Harmonic Scalpel Versus Cavitron Ultrasonic Surgical Aspirator (CUSA)\n\nIntroduction The mode of parenchymal transection in hepatic resection has been a topic of great debate for decades. Many resections have now evolved into laparoscopic , and robotic-assisted procedures to limit morbidity. Morbidity and mortality after hepatic resection has progressively improved over the years due to improved equipment, operative technique \\[3\\], and anesthetic management. Prior to 1980, mortality rates were reported to be in the 10-20% range with many deaths related to perioperative hemorrhage. Now perioperative mortality has dropped significantly to approximately 5%.\n\nThe clamp-crush technique, first reported in 1974, has been used for decades and remains the standard means of parenchymal division for many surgeons. Control of intraoperative hemorrhage has been one of the principle technical problems in advancing liver surgery. Excess blood loss and intraoperative blood transfusions have been shown to be associated with increased perioperative mortality and morbidity including an increased rate of hepatocellular carcinoma recurrence . Transfusions are also associated with increased infections and with increased cost. Costs of blood transfusions were recently examined in surgical patients.\n\nMany devices are now available to surgeons for division of the liver parenchyma in both open and minimally invasive surgery including: the CUSA (Tyco Healthcare, Mansfield, MA), Harmonic Scalpel (Ethicon Endo-Surgery, Cincinnati, OH, USA), Ligasure (Valley Lab, Tyco Healthcare, Boulder, CO, USA), Tissue Link (Salient Surgical Technologies, Portsmouth, NH), water-jet dissection, radiofrequency, microwave assisted resection, vascular staplers, and others In this study, we looked at the TissueLink bipolar sealer device that was used in combination with the CUSA in group 1 termed the CUSA\u002FTissueLink group, and the Harmonic Scalpel in the group 2 termed Harmonic Scalpel\u002FTissueLink. The TissueLink uses radiofrequency energy focused near the end of the device for electrocautery and a low volume saline drip that produces ohmic heat causing precoagulation of hepatic parenchyma. The saline keeps the temperature at or below 100 C to avoid eshcar formation ultimately helping prevent delayed biliary leak and hemorrhage. The hemostatic effects of TissueLink are a result of its disruption of the collagen in blood vessels causing closing of the lumen .\n\nThe CUSA, a commonly used device in hepatic resection, was used in combination with the TissueLink in this study. We previously described this combination of devices reporting a shorter length of hospital stay, decreased operative time, and decreased intraoperative blood transfusion . CUSA uses ultrasonic energy to fragment and aspirate parenchymal tissue. This exposes biliary as well as vascular structures that may then be closed in a variety of ways at the surgeon's discretion. It allows for a precise transection plane allowing preservation of normal hepatic tissue .\n\nThe Harmonic Scalpel, used in this study in combination with the TissueLink, utilizes ultrasonic vibration of two blades causing destruction of hydrogen bonds. This disruption of hydrogen bonds causes protein denaturization coagulating small vessels of 3 mm diameter. The parenchyma is also cut when the blades move in a saw-like fashion In this study, we evaluated the safety and efficacy of two different techniques described above for the division of the hepatic parenchyma in order to improve perioperative outcomes.",[119,120,24,121],"Liver Resection","Liver Tumours","Trauma Abdomen",[123,124,125,126],"liver resection","CUSA","Cavitron Ultrasonic Surgical Aspirator","Harmonic","NOT_YET_RECRUITING","2025-08-26",{"date":130,"type":35},"2025-08-27",{"date":132,"type":20},"2025-08-22",{"date":134,"type":20},"2026-12-30",{"name":136,"class":42},"Sohag University",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":146,"conditions":147,"keywords":150,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":4},"100575439","study-of-oxidized-albumin-in-liver-transplant-patients-100575439","NCT06772298","Study of Oxidized Albumin in Liver Transplant Patients","SALT","Inclusion Criteria:\n\n* Patients on waiting list for liver transplantation\n\nExclusion Criteria:\n\n* none",{"count":145,"type":20},10,"The overall goal is to describe the oxidation state of albumin before, during and after liver transplantation. This is a pilot observational study in which the oxidative state in 10 patients undergoing liver transplantation will be described. Samples for analysing the oxidation state of albumin, general oxidative damage and anti-oxidant state, the activation of the complement system and factors involved in coagulation will be obtained before transplantation, before and after reperfusion of the portal vein and on postop days 1, 2 and about 30.",[148,149,24],"Liver Failure","Liver Cirrhosis",[151,152,153],"Oxidised albumin","Complement","Coagulation","2025-01-08",{"date":156,"type":35},"2025-01-13",{"date":158,"type":20},"2025-02-01",{"date":160,"type":20},"2026-12-31",{"name":162,"class":163},"Region Stockholm","OTHER_GOV",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":174,"conditions":175,"keywords":176,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":4},"100566706","nomogram-for-predicting-biliary-complication-100566706","NCT06658665","Nomogram for Predicting Biliary Complication","Nomogram for Predicting Postoperative Early Biliary Complication in Adult Patients Following Liver Transplantation: a Retrospective Study","NPBC","Inclusion Criteria:\n\n①Patients aged ≥ 18 years.\n\n②Patients who underwent their first liver transplantation at Sun Yat-sen University First Affiliated Hospital between January 1, 2016, and December 31, 2021.\n\nExclusion Criteria:\n\n* Living donor liver transplantation. ② Split liver transplantation.\n\n  * Multi-organ transplantation. ④ Missing preoperative baseline indicators and postoperative ultrasound examination results.\n\n    * Patients undergoing re-transplantation.",{"count":173,"type":20},900,"The goal of this observational study is to develop a nomogram model to predict biliary complications within 90 days in adult patients after liver transplantation. The main questions it aims to answer are:\n\nCan the nomogram predict biliary complications within 90 days in adult patients after liver transplantation? What about the performance of the nomogram? Researchers will compare patients' preoperative variables, intraoperative factors, and postoperative outcomes to see what factors are associated with biliary complications.Subsequently, multivariable logistic regression analysis was conducted to evaluate the factors associated with biliary complications occurring within 90 days post-liver transplantation. Finally, a nomogram was developed.",[24],[177,178,179,180],"liver transplantation","biliary complication","nomogram","prediction model","2024-10-24",{"date":183,"type":35},"2024-10-26",{"date":185,"type":20},"2024-11-01",{"date":187,"type":20},"2024-12-30",{"name":189,"class":42},"Sun Yat-sen University",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":84,"phases":198,"briefSummary":199,"conditions":200,"keywords":203,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":43},"100563420","effects-of-aerobic-and-resistance-exercises-on-inpatients-liver-transplantation-recipients-100563420","NCT06615934","Effects of Aerobic and Resistance Exercises on Inpatients Liver Transplantation Recipients","Comparing the Effects of Aerobic and Resistance Exercises With Routine Physiotherapy in Inpatients Immediately After Liver Transplantation on Muscle Strength, Functional and Aerobic Capacity, and Blood Biomarkers","Inclusion Criteria:\n\n1. Patients who undergo elective surgery after the approval of the liver transplant commission.\n2. Having an underlying liver disease with metabolic disorder (as determined by the Liver Transplantation Commission)\n3. Absence of transplantation of other organs\n4. No re-transplantation of the liver\n5. Age more than 18 years\n6. Ability to participate in initial evaluations\n7. Patient's ability to understand questionnaire questions\n\nExclusion Criteria:\n\n1. The patient's lack of satisfaction with continuing cooperation for any reason\n2. Re-transplantation up to 3 months after discharge\n3. Facing the patient with early allograft dysfunction or primary nonfunction\n4. Encountering the criteria of non-implementation of the intervention during 50% of the days of stay in the hospital or more\n5. Patients with Postoperative respiratory failure (Extubation \\> 48 hours)",{"count":53,"type":20},[116],"The prevalence of chronic liver disease and primary liver cancer is still increasing on a global scale, and so are their associated deaths.\n\nCompared to other diseases, death from liver disease often means premature death, because two-thirds of the lives lost are working years.\n\nLiver transplantation (LT) is an important and life-saving treatment option for the treatment of congenital metabolic disorders, acute liver failure, end-stage chronic liver disease (ESLD) and primary liver cancers.\n\nModern liver transplantation is characterized by significant improvements in post-transplant patient survival, graft survival, and quality of life.\n\nImpaired physical fitness of patients with end-stage liver disease often persists after liver transplantation and compromises post-transplant recovery.\n\nPrior to liver transplantation, excess ammonia taken up by skeletal muscle is a major metabolic driver of muscle wasting in end-stage liver disease and mainly inhibits the mTOR signaling pathway that supports muscle protein synthesis.\n\nBecause excess ammonia is no longer present after transplantation, recovery of muscle mass and function can be expected in patients. However, immunosuppression with calcineurin inhibitors that inhibit the mTOR signaling pathway may improve lethal length.\n\nIt is also thought that post-transplant treatment regimens contribute to delayed recovery of decreased bone mineral density and increased fracture risk.\n\nGreater muscle mass, as measured by creatinine clearance at 1 year after transplantation, was associated with longer recipient and allograft survival.\n\nThe results of previous studies indicate low cardiovascular fitness in patients after liver transplantation.\n\nSince after liver transplantation, cardiovascular diseases cause 19 to 42% of deaths not related to the liver, performing aerobic exercises to obtain and maintain cardiovascular fitness after liver transplantation can reduce the mortality rate. After transplanting, reduced significantly.\n\nConsidering the important role of the immune system in transplant rejection, the safety of sports training is very important in terms of not over-activating the immune system and endangering the life of the transplanted tissue. In previous studies related to exercise and immune system activity and inflammatory cytokines after transplantation, it has been shown that moderate exercise including aerobic and resistance exercises can inhibit inflammatory cytokines and have beneficial effects on the immune system.\n\nHigh levels of tumor necrosis factor-alpha (TNF-α) in the period after transplant surgery are associated with an increased risk of transplant rejection.\n\nAerobic exercise reduces levels of inflammatory cytokine TNF-α and markers of liver function in patients with chronic liver diseases.\n\nAccording to this evidence, it seems that doing sports exercises is effective in reducing the risk of transplant rejection and modulating the patient's immune system. Acute graft rejection occurs days to weeks after transplantation. The immune system can see the transplanted organ as foreign and attack it, destroy it and lead to transplant rejection.\n\nConsidering the mentioned benefits of exercise therapy after liver transplantation, it is possible that the early start of exercise therapy in the hospitalization phase leads to a reduction in the risk of transplant rejection and improvement of allograft residues in patients after liver transplantation.\n\nConsidering that the current evidence shows that there is no use of a specific rehabilitation protocol in the hospitalization phase of patients after liver transplantation, we intend to evaluate its effects with changes in the common physiotherapy program in these departments according to the specific conditions of these patients. In other words, despite the acceptable therapeutic effects, the use of a combined protocol of aerobic and resistance exercises in the hospitalization phase of these patients has not been reported so far.",[24,201,202],"Liver Transplant; Complications","End-stage Liver Disease",[204,205,206,207],"physiotherapy","aerobic exercise","resistance exercise","liver transplant recipients","2024-09-26",{"date":210,"type":35},"2024-09-27",{"date":212,"type":20},"2024-10-01",{"date":214,"type":20},"2025-01-15",{"name":216,"class":42},"Tehran University of Medical Sciences",{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":224,"enrollmentInfo":225,"targetDuration":4,"studyType":84,"phases":227,"briefSummary":228,"conditions":229,"keywords":231,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":4},"100496906","liver-transplantation-with-two-stage-liver-resection-in-unresectable-liver-cancer--metastases-or-emd-stage-liver-disease-ltlr-lc-100496906","NCT05750329","Liver Transplantation With Two-stage Liver Resection in Unresectable Liver Cancer , Metastases or Emd-stage Liver Disease (LTLR-LC)","Clinical Study of Adjuvant Liver Transplantation Combined With Two-stage Hepatectomy for the Treatment of Patients With Unresectable Primary Hepatocellular Carcinoma, Colorectal Cancer With Liver Metastases, or End-stage Liver Disease: a Multicenter, Prospective, Single-arm Study","Inclusion Criteria:\n\n1. aged 18-75 years;\n2. patients with unresectable primary hepatocellular carcinoma or colorectal cancer with liver metastases who also meet the following criteria: tumor shrinkage (still unresectable) or no significant progression after a first-line chemotherapy regimen of 6-8 weeks; no other abdominal metastases or 1-3 resectable pulmonary metastases;\n3. patients with end-stage liver disease;\n4. preoperative Child classification of A or B, able to tolerate the subsequent surgical program\n5. Signed informed consent Note: One of the second or third criteria needs to be fulfilled and all the rest of the selection criteria need to be fulfilled\n\nExclusion Criteria:\n\n1. Extrahepatic tumor burden (except for resectable lung metastases) and\u002For macrovascular tumor infiltration\n2. Tumor progression during chemotherapy or important comorbidities that affect surgery\n3. Uncorrectable cardiopulmonary disease with high surgical risk\n4. Anatomical abnormalities that preclude liver transplantation\n5. Persistent non-compliance with medical care\n6. Combined with other diseases such as AIDS that affect surgery or tumor progression","75 Years",{"count":226,"type":20},30,[116],"Colon cancer and primary liver cancer are common malignant tumors with low survival rate worldwide, and unresectable primary liver cancer and colon cancer liver metastases have worse prognosis. End-stage liver disease is equated with advanced liver disease, liver failure and decompensated cirrhosis because they are generally irreversible. Liver transplantation is a treatment option for the above-mentioned patients and is expected to improve the prognosis of the patients, but the biggest problem faced by such patients is the shortage of donor livers. Recently, a new surgical modality, resection and partial liver segment 2-3 transplantation with delayed total hepatectomy (RAPID), can greatly alleviate these problems.Based on clinical surgical experience, our center proposes and designs a clinical study of adjuvant liver transplantation combined with two-stage hepatectomy in the treatment of patients with unresectable primary liver cancer, colorectal cancer liver metastases, or end-stage liver disease. By improvement of RAPID operation, the safety and efficacy of this treatment method in patients with those disease were evaluated.",[24,230,202],"Hepatic Cancer",[177,232],"Hepatectomy","2023-08-03",{"date":235,"type":35},"2023-08-07",{"date":237,"type":20},"2023-08",{"date":239,"type":20},"2026-12",{"name":241,"class":42},"RenJi Hospital"]